Aims/hypothesis Heart failure (HF) incidence in diabetes in both the presence and absence of CHD is rising. Prospective population-based studies can help describe the relationship between HbA 1c , a measure of glycaemia control, and HF risk.
Introduction
Heart failure (HF) affects more than five million individuals in the US population and has a yearly incidence of more than 500,000 cases. The burden is magnified in individuals with diabetes, in whom incidence rates are two to five times higher [1] . Clinical trials of tight glycaemic control and cardiovascular events have had mixed results [2, 3] . Diabetes-associated HF has been considered as a microvascular complication, but it is very difficult to exclude the confounding impact of associated CHD and its myocardial dysfunction sequelae.
HbA 1c , an important measure term of glycaemic control, reflects endogenous glucose levels over the previous 2-3 months [4] . In persons with diabetes, HbA 1c is related to the development of microvascular disease and is at the centre of the clinical management of hyperglycaemia [5] . A few previous epidemiological studies have looked at the relationship between HbA 1c and HF [3, 6, 7] . In the present study, we analysed data from the Atherosclerosis Risk in Communities (ARIC) study to investigate the relationship between HbA 1c and risk of HF in a community-based sample of persons with diabetes. We hypothesised that HbA 1c would be independently associated with HF incidence in persons with diabetes in the community. There is increasing evidence that diabetes results in cardiomyopathy independently of CHD [8] . Therefore, we looked separately at the relationship between glycaemic control and HF by the presence and absence of CHD at baseline and during follow-up.
Methods

Study population and design
The ARIC study is a community-based cohort study of 15,792 people aged 45-64 years at baseline sampled from four US communities [9] . The first clinical examination took place during 1987-1989, with three follow-up visits, one approximately every 3 years. A wealth of information on cardiovascular disease risk factors is available for all participants. Visit 2 (1990 Visit 2 ( -1992 ) was the only visit for which stored whole blood samples were available for the measurement of HbA 1c , and was the baseline visit for the present study. We analysed prospective cohort data from persons with diabetes with follow-up for incident HF through to 1 January 2003. Considering that the incidence of HF could be strongly influenced by prevalent CHD, the study population was divided accordingly. The study was approved by the Institutional Review Boards or all participating institutions and all individuals gave informed consent.
Baseline variables and data collection
Exposure: HbA 1c Frozen whole blood samples from ARIC Visit 2 were thawed and assayed for HbA 1c using HPLC (Tosoh Corporation, Tokyo, Japan). We have previously demonstrated the reliability of measurements from these stored samples [10] .
Outcome: HF Study participants with evidence of prevalent HF were excluded from analyses. Prevalent HF was assumed if there was evidence of manifest HF stage 3, applying the Gothenburg criteria that require the presence of specific cardiac and pulmonary symptoms as well as medical treatment of HF [11, 12] .
Incident HF was defined either as death from HF in any position on the death certificate or as the first HF hospitalisation in any position of the hospital discharge list. Hospitalisations were coded as HF (428) using the International Classification of Diseases Code, Ninth Revision (ICD-9), and deaths were coded as HF (428 and I50) using the ICD-9 and ICD-10 codes (http://www.who.int/ classifications/icd/en/).
Other variables of interest
Demographics Age, sex, race (white and African-American), level of education (basic [<12 years of education]; intermediate [12-16 years] ; and advanced [>16 years]), health insurance status (present or absent), cigarette smoking status (current, former or never) and alcohol consumption status (current, former or never) information were obtained by a trained interviewer at the baseline visit.
Diabetes Diabetes was defined as a fasting glucose level of ≥7.0 mmol/l (≥126 mg/dl; reported minimum of 8 h of fasting prior to visit), a non-fasting glucose level of ≥11 mmol/l (≥200 mg/dl), a self-reported physician diagnosis of diabetes, or medical treatment for diabetes at either the first or second ARIC examination.
Prevalent CHD CHD was defined as a prior myocardial infarction by electrocardiogram, a history of physiciandiagnosed myocardial infarction, or a prior coronary reperfusion procedure at either Visit 1 or Visit 2.
Physical measurements Resting seated systolic BP (SBP) was recorded by certified technicians using a random-zero sphygmomanometer, and included in the analyses as the average of the second and the third of three readings. BMI was calculated as measured weight (kg)/height (m) 2 . WHR was calculated according to a standardised protocol [9] .
Medications BP and diabetes medication use were verified by the inspection of medication bottles. Use of antihypertensive medication at baseline included the use of α-, β-and calcium channel blockers, ACE inhibitors, diuretics, or a combination thereof.
Laboratory measurements Fasting blood samples were drawn, frozen, centrifuged and shipped to ARIC study laboratories for analysis. Kidney function was assessed by calculating the estimated GFR using the simplified Modification of Diet in Renal Disease equation [13] .
Statistical analyses
Out of 2,099 participants with diabetes, analyses were limited to 1,827 participants after excluding prevalent HF (n=204), race other than African-American or white (n=4), and missing information on HbA 1c (n=31) and prevalent CHD (n=33).
Demographic and health characteristics by CHD, HF and HbA 1c status were compared using χ 2 tests, t tests and ANOVA as applicable. Crude HF incidence rates and 95% CIs were calculated using time-to-event methods. The proportion of individuals remaining free of incident HF at any time during follow-up was calculated using the Kaplan-Meier method. For all survival analyses, the follow-up time was defined as the period from entry into the study (Visit 2) to the first HF hospitalisation, death from HF, or up to the time an individual left the study; 1 January 2003 was considered the end of the follow-up if the individuals were free of HF. HbA 1c was divided into clinical cut-off points and risk of HF was compared across these categories using Cox proportional hazards models. We compared models with and without adjustment for major HF risk factor, comparing nested models using likelihood ratio tests. We also formally tested for interactions between HbA 1c and sex, ethnicity and prevalent CHD. The proportionality assumption of all Cox models was assessed by inspecting the complementary log(−log [survival function]) curves (where log is ln).
We also identified a subgroup of newly diagnosed diabetes patients with elevated blood glucose at baseline without a previous history or use of medications for diabetes, for whom the fully adjusted model was implemented for comparison with the original group.
We performed three sensitivity analyses. First, in the group without prevalent CHD at baseline, we assumed that CHD and HF could act as competing events and censored all participants who developed CHD prior to HF at the date of the CHD event. Essentially, this analysis has as the outcome HF occurring in individuals who have no clinical CHD at the time of first HF hospitalisation or death. Second, we considered the impact of excluding different lag-times (1-5 years) to increased HF risk, for the entire period of follow-up and when we censored all observations at 5 year follow-up. Finally, we ran our models on those participants who were not using any medication at baseline. All analyses were conducted using Stata version 9.2 software [14] .
Results
The average follow-up (SD) for the 1,827 individuals with diabetes available for analysis was 9.9 years (3.0). Among our baseline diabetic study population, 48.4% were male, 39.4% were African-American, and the mean age (SD) was 58.0 (5.7) years. Over the course of follow-up, 384 study participants (21.1%) died.
Baseline characteristics
The baseline characteristics of participants by clinical categories of HbA 1c (<6%, 6-7%, 7-8% and >8%) are presented in Table 1 . For participants without CHD at baseline, higher levels of HbA 1c were associated with female sex, African-American race, no health insurance, and higher WHR and LDL-and HDL-cholesterol levels. The proportion of never smokers, former or never drinkers, and the use of antihypertensive and glucose-lowering medications also increased with HbA 1c levels. In comparison, for participants with CHD at baseline, there were no clear differences in baseline characteristics, with the exception of race and use of glucose-lowering medications.
Incidence of HF
HF was documented in 328 (17.9%) of the 1,827 participants, with only 15 events (4.5%) being identified from death certificates. The incidence rates for the overall study population and for participants without CHD and with CHD at baseline were 18.1, 15.5 and 56.4 per 1,000 person-years, respectively. The incidence rates according to HbA 1c clinical cut-off points and CHD status at baseline are shown in Fig. 1 . For participants without CHD at baseline, there was an increase in HF incidence with higher HbA 1c levels. The pattern was not as clear among the participants with pre-existing CHD at baseline.
Survival analysis
The cumulative incidence of HF by categories of HbA 1c according to clinical cut-points and stratified by status of CHD at baseline is shown in Fig. 2 . For those participants without prevalent CHD at baseline, the difference among the cumulative incidence curves are clearly visible after the mean follow-up period of 9.9 years (log-rank test: p<0.001). For those participants with prevalent CHD at baseline, the HF risk was higher and the association with baseline HbA 1c not significant, with a possible threshold of increased risk at an HbA 1c level of 8% (Fig. 2) .
Cox proportional hazards analysis with three different models was used to obtain HRs of HF incidence for HbA 1c as a continuous and categorical (HbA 1c clinical cut-points) 
2).
Incident CHD and HF were considered competing events and the follow-up time of individuals without prevalent CHD at baseline were censored at the time of the new CHD event if it occurred. In this analysis, which only includes HF events which occur in the absence of CHD, the HR of incident HF per 1% increase in HbA 1c remained significant (1.20 [95% CI 1.11-1.29]) (Fig. 3) .
Additional analyses showed that estimated GFR was associated with risk of HF [15] but did not confound the associations reported here with HbA 1c . There was no difference in the HR of HF associated with higher HbA 1c by sex (p=0.73) or prevalent CHD (p=0.47). A lag-time analysis was performed for all the different models. Lag-times from 0 to 5 years did not change the results, with the exception of the recently diagnosed diabetes sensitivity analysis group. In this group, the HRs increased with the increase in the lag-time 
Discussion
Our findings suggest that HbA 1c is an independent risk factor for HF in adults with diabetes regardless of the presence of CHD at baseline or the development of CHD during follow-up. These findings are consistent with previous work by Iribarren et al. [6] . These data provide support for the theory that hyperglycaemia can cause damage to the myocardium (2;11;20) . Our findings are consistent with and extend previous prospective studies in patients with type 2 diabetes [4, 6, [16] [17] [18] [19] . In the observational analysis of the UKPDS [3] study, the HR for HF in newly diagnosed diabetes patients was 1.16 (95% CI 1.03-1.26) per 1% higher updated HbA 1c , while baseline HbA 1c was not significant (1.00 [95% CI 0.88-1.11]). When we considered only participants with a recent diagnosis of diabetes, HbA 1c measured at baseline was also not significantly associated with HF 1.10 (95% CI 0.93-1.32). This could be caused also by the low HbA 1c levels seen in the overall study population, which included a large number of individuals with undiagnosed diabetes (two-thirds of those without CHD have HbA 1c <7% and >40% have HbA 1c <6%). Iribarren et al. [6] found an HR for HF of 1.08 (95% CI 1.05-1.12), using a very similar HF definition to ours. Nichols et al. [7] conducted a nested case-control study of 8,231 Kaiser Permanente Medical Care Program of Northern California Diabetes Registry, which includes all members with type 2 diabetes and reported an HR of 1.32 (95% CI 1.23-1.41) per 1% higher updated mean HbA 1c for incident HF. The stronger association observed in the latter study may have resulted from the inclusion of outpatients and the use of average HbA 1c over a longer period of time (almost 5 years).
Overall, the HbA 1c -HF association observed in these previous studies is similar to our results. Other less-sensitive markers such as glycaemia have also been associated with increased risk of HF [20] .
One possible problem for establishing a causal relationship between poor glycaemic control and HF could be the lag-time needed for myocardial damage. The amount of time from exposure to elevated glucose levels to resulting myocardial damage is uncharacterised. We performed a lagtime analysis (from 0 to 5 years) for the non-prevalent CHD participants (total group and those with recently diagnosed diabetes) keeping the total amount of follow-up and limiting the follow-up to 5 years. Our findings showed that for all these analysis, HbA 1c remained a marker of increased HF incidence. n, number of people; e, number of events. Censoring CHD events analysis shows the HR of HF events that occurred prior to any CHD at baseline or during follow-up. Newly diagnosed diabetes analysis limits the analysis to participants with elevated blood glucose without a history of diabetes diagnosis or treatment with diabetes medication. Lag-time analysis limits the events to those occurring only after 2 years of follow-up and limits the follow-up to 5 years of observation We did not adjust for the use of diabetes medications, as any medication use will directly influence HbA 1c levels and inclusion of medications in our multivariable analysis may have resulted in overadjustment. Newer oral glucoselowering medications have been suggested to be a risk factor for incident HF [21] , but the use of these medications was extremely low in the ARIC cohort, established more than 20 years ago. As such, this study population provided an opportunity to assess the HbA 1c -HF association in the absence of the possible confounding effect of these medications. Analyses limited to participants without CHD at baseline who were not taking diabetes medications did not change our results (1.22 [95% CI 1.10-1.35]). Nonetheless, we cannot rule out some effect of glucoselowering medications over the entire follow-up.
Other limitations of our study include the lack of cardiac imaging data to detect subclinical myocardial dysfunction, no measures of CHD severity, and the small number of individuals with prevalent CHD (n=159). This study focused on HF hospitalisation or death, which excludes milder events and relies on hospital coding practices [22] . Duration and intensity of treatment of diabetes were not captured. Evaluation risk of clinical outcomes on the basis of a single baseline measurement has inherent limitations but does reflect the common clinical setting, in which the clinician is interested in the interpretation of a single HbA 1c value. Our ability to characterise the association of HbA 1c level with HF risk was limited by sample size among individuals with CHD.
Our study has a number of strengths. First, the ARIC study has rigorous measurements of cardiovascular risk factors. Second, we were able to exclude prevalent HF cases based on a wide range of criteria, using a highly sensitive definition. Finally, our study sample was from a multi-ethnic, community-based population, contributing to the generalisability of these results.
It is likely that higher HbA 1c reflects the deleterious effects of chronic hyperglycaemia on the heart muscle, the collective effects of which have been labelled 'diabetic cardiomyopathy' [23] . This information supports the recommendations of the American Heart Association/American College of Cardiology guidelines for HF, highlighting the need to identify persons at high risk of developing the syndrome for preventive measures [5] .
Our finding that after adjustment for additional HF risk factors such as BP (model 3) the risk associated with HbA 1c between 6% and 7% was not significantly elevated over <6.0% is provocative; consistent UKPDS primary analyses did not show a definitive benefit for glycaemic control with respect to cardiovascular endpoints, including HF. The recently published Action to Control Cardiovascular Risk in Diabetes (ACCORD) study terminated the tight glycaemic control arm early because of a small but significant increase in all-cause mortality. No benefit for tight glycaemic control was observed for HF, a secondary endpoint in this trial [24] . Similarly, the ADVANCE trial did not demonstrate any benefit of intensive blood glucose control for HF risk [25] . In the UKPDS and ACCORD trials, it is not possible to separate the effects of tight glucose control from potential adverse effects (with respect to cardiovascular disease) of the drugs used, thus these results do not completely refute the hypothesis that lower HbA 1c is advantageous. However, the results may reflect a glycaemic threshold. In other words, it is only in the face of significant hyperglycaemia that diabetic cardiomyopathy predominates as an aetiology of clinical HF, over and above the effects of hypertension and ischaemic heart disease. In the light of these findings, it seems that keeping the levels of HbA 1c according to those recommended by standard guidelines may be beneficial regarding HF incidence.
The American Diabetes Association Clinical Practice Guidelines do not specifically include HF as a complication of diabetes [26] . Diabetic cardiomyopathy remains a controversial issue, as a great part of the increased risk for HF in diabetic patients is attributed to incident CHD. Our data support reduction of HF risk as a potential benefit of improved glycaemic control, provided specific medications do not have harmful effects on myocardial function. Longterm clinical trials of specific glucose-lowering strategies on HF risk in persons with diabetes are needed.
In summary, a single measure of HbA 1c is an independent predictor of incident HF hospitalisation or death over the next decade in a community-based cohort of individuals with diabetes, regardless of the presence of CHD at baseline or the development of CHD during follow-up. Since the main results of the UKPDS trial did not show a reduction in macrovascular disease risk and no reduction in HF incidence was found in the ACCORD and ADVANCE trials, there is on-going debate regarding the role of hyperglycaemia in the development of cardiovascular complications [3, 24, 25] . Accumulating epidemiological evidence suggests that HbA 1c may be an important risk factor for cardiac disease. Our results add to this growing literature, supporting the hypothesis that improvements in glycaemic control may also reduce the risk of HF above and beyond any risk reduction for CHD, but optimal treatment strategies and targets remain controversial.
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